EVMN · Evommune, Inc.

Track EVMN — free

$10.54 -0.02 (-0.19%) At close · Sep 11

Russell 2000 member Rebalance outlook locked

Market Cap

$382.52M

36.29M

Up next

Latest filing: 10-Q

filed Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$10.00M

Trailing 12 months

Net income (TTM)

−$94.67M

Trailing 12 months

Revenue growth YoY

+85.7%

Year over year

Operating margin

-1,018.9%

Trailing 12 months

P / E (TTM)

1.9

Trailing earnings · reciprocal yield 52.4%

FCF yield

-19.5%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$200.79M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+2,245.4%

Year over year · more shares

Price change (1Y)

—

Trailing year

Short interest

12.0%

Latest settlement · 11.6 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Strong Sell Momentum Very Weak Sentiment Bullish Fundamentals Strong Quant / Vol Very High

Market backdrop VIX 15.8 · calm Equity put/call 0.60

Technical

price trend

Strong Sell

50 / 200-day cross No cross

Price vs 200-day avg −47%

below

Price vs 50-day avg −17%

below

RSI (14) 33

neutral

MACD trend Negative

52-week position 0%

near low

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Weak

1-month return −25%

trailing

6-month return −55%

trailing

YTD return −38%

this year

Relative strength −73%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $13 › 200d $20 — 200d above 50d

Institutional flow Accumulating

+27% holders QoQ · +43 funds added

Insider flow Accumulating

Net +$146.3K over 90 days · 0% sells

Short interest Falling

12.03% of float · ▼ -7.1% MoM · 11.6 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

107 holders — 13F breadth

Squeeze score 59

elevated · 0–100

Fundamentals

Strong

Revenue growth +86%

Y/Y

EPS growth +75%

Y/Y

Free cash flow $-76.7M

Quant / Vol

risk profile

Very High

Volatility 124%

annualized · 1-yr

Max drawdown −67%

past year

ATR 8.7%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell

4 · 3 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−47% Bearish

Price vs 50-day avg

−17% Bearish

RSI (14)

33 Neutral

MACD trend

Negative Bearish

52-week position

0% Bearish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $13 › 200d $20 — 200d above 50d

Institutional flow Accumulating

+27% holders QoQ · +43 funds added

Insider flow Accumulating

Net +$146.3K over 90 days · 0% sells

Short interest Falling

12.03% of float · ▼ -7.1% MoM · 11.6 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

107 holders — 13F breadth

Price context

position in its available closing range

Range low $11 Now $11 · 0% Range high $32

vs 200-day avg -47% vs 50-day avg -17%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
EVMN Evommune, Inc. this stock	$382.52M	-38.4%	+85.7%	—	12.0%
VRTX Vertex Pharmaceuticals Inc / Ma	$130.40B	+13.7%	+46.2%	30.0	1.8%
REGN Regeneron Pharmaceuticals, Inc.	$81.67B	+1.2%	+20.8%	19.6	2.5%
ARGX Argenx SE	$61.60B	+17.1%	—	—	2.0%
CSLLY Csl Ltd	$57.41B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

107

% held: 98.2%
Net QoQ: +1.1M sh
Top holder: EQT Fund Management S.a r…

Held Float

View

Held by Funds

Fund positions

115

View

Short & Settlement

Short Interest Falling

Shares short

4.4M

Days to cover: 11.6d
Change: -332.7K sh

View

Short Volume

Short vol %

39%

As of: Sep 11, 2026

Short Total

View

Fails to Deliver

FTD shares

5.6K

Value: $74.7K
As of: Aug 7, 2026

View

Off-Exchange

Off-exchange %

44.5%

Week of: Aug 3, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net buying

Net (90d)

+$146.3K

Buyers / Sellers: 2 / 0

Buyers Sellers

View

Financials

Revenue (FY)

$13.0M

Net income (FY): $-68.9M
EPS diluted: $-11.22

View

Filings

SEC Filings

Latest

8-K

Filed: Sep 9, 2026
This year: 15

View

Proposed Sales

Value

$427.2K

Shares: 20.0K
Filed: Jun 22, 2026

View

Exempt Offerings

Offering

$57.5M

Filed: Jan 8, 2025

View

Earnings & Events

Earnings Calls

Last call

Jun 2, 2026

View

Performance

	5D	20D	120D	MTD	YTD
EVMN	-12.2%	-25.1%	-54.8%	-16.8%	-38.4%
SPY	-1.2%	-1.8%	+17.8%	-0.4%	+12.1%
vs SPY	-11.0%	-23.3%	-72.7%	-16.4%	-50.5%

Key facts CIK 2044725 CUSIP 30054Y107 13F (30d) 71 filings 71 filers Visit website Investor relations

EVMN · Evommune, Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance